所有图片(1)
别名:
棒酸钾
经验公式（希尔记法）:
C8H8NO5K
CAS号:
分子量:
237.25
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
推荐产品
等级
analytical standard
质量水平
产品线
VETRANAL®
保质期
limited shelf life, expiry date on the label
技术
HPLC: suitable
gas chromatography (GC): suitable
应用
agriculture
clinical
environmental
forensics and toxicology
pharmaceutical (small molecule)
格式
neat
储存温度
2-8°C
SMILES字符串
[K+].[H][C@@]12CC(=O)N1[C@@H](C([O-])=O)C(\O2)=C\CO
InChI
1S/C8H9NO5.K/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4;/h1,6-7,10H,2-3H2,(H,12,13);/q;+1/p-1/b4-1-;/t6-,7-;/m1./s1
InChI key
ABVRVIZBZKUTMK-JSYANWSFSA-M
正在寻找类似产品? 访问 产品对比指南
一般描述
克拉维酸钾是奥沙那南的衍生物，属于β-内酰胺酶抑制剂。它可与青霉素类抗生素联合使用，使它们对β-内酰胺酶产生耐药性。
应用
该分析标准品可用于：
- 利用毛细管电泳（CE）结合电容耦合非接触式电导检测法，对药物制剂中的阿莫西林和克拉维酸钾（C4D）同时进行分析
- 建立一种稳定性指示的高效液相色谱（HPLC）法，并结合质谱（MS）技术，测定阿莫西林、克拉维酸钾及其杂质在其联合剂型中的含量
- 使用紫外分光光度法对克拉维酸钾和阿莫西林三水合物在其原料药、联合片剂制剂和人类尿液样本中进行残留分析
- 利用基于HPLC法的二极管阵列检测器（DAD），在静脉注射的同时测定美罗培南和克拉维酸钾及其降解杂质的含量
- 利用毛细管区带电泳法（CZE），测定联合市售出制剂中阿莫西林和克拉维酸的含量
生化/生理作用
β-内酰胺酶抑制剂，通常加入阿莫西林以提高其功效。
其他说明
有关合适的仪器技术的更多信息，请参阅产品′的检验报告。想要获得更多支持，请联系技术服务部。
法律信息
VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany
警示用语：
Danger
危险分类
Flam. Sol. 2 - Resp. Sens. 1 - Self-heat. 2 - Skin Sens. 1
补充剂危害
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
监管及禁止进口产品
David Baunoch et al.
Infection and drug resistance, 14, 3275-3286 (2021-08-28)
Studies have shown that multiple genes influence antibiotic susceptibility, but the relationship between genotypic and phenotypic antibiotic susceptibility is unclear. We sought to analyze the concordance between the presence of antibiotic resistance (ABR) genes and antibiotic susceptibility results in urine
Marisa L Winkler et al.
Journal of medicinal chemistry, 56(3), 1084-1097 (2012-12-21)
Inhibitor resistant (IR) class A β-lactamases pose a significant threat to many current antibiotic combinations. The K234R substitution in the SHV β-lactamase, from Klebsiella pneumoniae , results in resistance to ampicillin/clavulanate. After site-saturation mutagenesis of Lys-234 in SHV, microbiological and
Yoram Fleissig et al.
Oral surgery, oral medicine, oral pathology and oral radiology, 113(3), e1-e3 (2012-06-09)
A 58-year-old woman presented to the Oral and Maxillofacial Surgery Clinic experiencing severe limited mouth opening and exposed bone in the socket of the right mandibular third molar 8 months following the extraction of the tooth. The patient had been
Ximena Gonzalo et al.
The Journal of antimicrobial chemotherapy, 68(2), 366-369 (2012-10-17)
To: (i) assess if amoxicillin/clavulanate is a useful option for the management of multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB); (ii) assess if meropenem/clavulanate is active against Mycobacterium tuberculosis at concentrations achievable in vivo; and (iii) determine whether there was inhibition of meropenem/clavulanate
B R Smith et al.
Drug intelligence & clinical pharmacy, 19(6), 415-420 (1985-06-01)
Potassium clavulanate is a novel beta-lactamase inhibitor, which, in combination, expands the spectrum of amoxicillin to include many amoxicillin-resistant organisms. Potassium clavulanate is excreted 30-50 percent unchanged renally and its plasma time-course parallels that of amoxicillin. Several studies suggest that
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门